Payment overview · 2025
General Payments
$382.98
7 reported records · 7 companies
Healthcare provider profile · identity verified
Rajankumar P. Patel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · CHERRY HILL, NJ · NPI 1396896023
Verified facts
What the public records show
CMS Open Payments records show Rajankumar P. Patel, M.D. received $382.98 in general payments during 2025 across 7 reported records.
Abbott Laboratories accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $179.38 | 46.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.87 | 32.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.88 | 4.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.51 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.78 | 4.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.58 | 4.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.98 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $382.98 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $179.38 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.87 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 645 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 117 |
| Metformin Hcl | Metformin Hcl | 427 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 93 |
| Losartan Potassium | Losartan Potassium | 308 | 84 |
| Lisinopril | Lisinopril | 255 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 47 |
| Gabapentin | Gabapentin | 205 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 169 | 49 |
| Carvedilol | Carvedilol | 161 | 39 |
| Glimepiride | Glimepiride | 159 | 42 |
| Alprazolam | Alprazolam | 158 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 46 |
| Jardiance | Empagliflozin | 145 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 33 |
| Famotidine | Famotidine | 139 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 43 |
| Azithromycin | Azithromycin | 138 | 102 |
| Sertraline Hcl | Sertraline Hcl | 135 | 21 |
| Furosemide | Furosemide | 132 | 39 |
| Omeprazole | Omeprazole | 128 | 40 |
| Januvia | Sitagliptin Phosphate | 122 | 19 |
| Mirtazapine | Mirtazapine | 122 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 30 |
| Simvastatin | Simvastatin | 114 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 28 |
| Metformin Hcl Er | Metformin Hcl | 103 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 93 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 26 |
| Trazodone Hcl | Trazodone Hcl | 91 | 27 |
| Eliquis | Apixaban | 89 | 24 |
| Ibuprofen | Ibuprofen | 74 | 27 |
| Farxiga | Dapagliflozin Propanediol | 71 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 13 |
| Atenolol | Atenolol | 69 | 16 |
| Buspirone Hcl | Buspirone Hcl | 69 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 18 |
| Alendronate Sodium | Alendronate Sodium | 67 | 18 |
| Aripiprazole | Aripiprazole | 66 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 15 |
| Montelukast Sodium | Montelukast Sodium | 64 | 24 |
| Divalproex Sodium | Divalproex Sodium | 63 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 13 |
| Glipizide | Glipizide | 58 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 15 |
| Prednisone | Prednisone | 54 | 17 |
| Levetiracetam | Levetiracetam | 53 | 13 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Amoxicillin | Amoxicillin | 52 | 39 |
| Potassium Chloride | Potassium Chloride | 52 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 13 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 22 |
| Nystatin | Nystatin | 43 | 26 |
| Ozempic | Semaglutide | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Latanoprost | Latanoprost | 41 | 11 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Naproxen | Naproxen | 40 | 29 |
| Lovastatin | Lovastatin | 39 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 11 |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 21 |
| Risperidone | Risperidone | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Lacosamide | Lacosamide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 22 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Alogliptin | Alogliptin Benzoate | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | 11 |
| Ramipril | Ramipril | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Methimazole | Methimazole | 20 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | 11 |
| Anastrozole | Anastrozole | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $382.98 · 7 records | Abbott Laboratories | FREESTYLE LIBRE 3, JARDIANCE, PAXLOVID, REXULTI, VOQUEZNA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error